文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

肥胖对接受ECMO的COVID-19 ARDS患者生存的影响:一项双向观察性队列研究结果

Impact of obesity on survival in COVID-19 ARDS patients receiving ECMO: results from an ambispective observational cohort.
PubMed 文献 · Ann Intensive Care · 2021-11-15
一句话结论在5个ICU的COVID-19重症ARDS接受ECMO的患者中,较高BMI与90天生存改善独立相关(OR 0.775与0.631),年轻年龄亦与生存改善相关。

该双向观察性队列纳入某大学医院5个ICU中2020年3月1日至11月30日连续收治的76例接受ECMO的COVID-19重症ARDS成人患者,主要目的是识别与90天生存相关的危险因素。ECMO启动前机械通气中位时间为6天(IQR 3-10),启动时中位PaO2:FiO2为71 mmHg(IQR 62-81)、PaCO2为58 mmHg(IQR 51-66)、动脉pH为7.33(IQR 7.25-7.38)。45例(59%)脱离ECMO,28天、60天和90天生存率分别为92%、62%和51%。多因素logistic回归两个模型(分别含RESP评分和PRESERVE评分)均显示较高BMI与较高90天生存相关(OR 0.775,95%CI 0.644-0.934,p=0.007;OR 0.631,95%CI 0.462-0.862),年轻年龄亦与90天生存相关(OR 1.1354,95%CI 1.004-1.285,p=0.044;OR 1.187,95%CI 1.035-1.362,p=0.014)。肥胖患者较非肥胖患者使用更高PEEP,呼吸系统顺应性略高。

要点

  • 76例接受ECMO的COVID-19重症ARDS患者中,28天、60天、90天生存率分别为92%、62%、51%,45例(59%)脱离ECMO。
  • 多因素logistic回归(含RESP评分模型)显示较高BMI与较高90天生存独立相关:OR 0.775(95%CI 0.644-0.934),p=0.007。
  • 多因素logistic回归(含PRESERVE评分模型)显示较高BMI与较高90天生存独立相关:OR 0.631(95%CI 0.462-0.862)。
  • 两个模型中年轻年龄均与90天生存相关:OR 1.1354(95%CI 1.004-1.285),p=0.044;OR 1.187(95%CI 1.035-1.362),p=0.014。
  • 肥胖患者较非肥胖患者通气时使用更高PEEP,呼吸系统顺应性略高。

适用人群与场景

  • 某大学医院5个ICU于2020年3月1日至11月30日连续收治的接受ECMO的COVID-19重症ARDS成人患者,共76例。

研究设计与关键结果

  • 双向观察性队列研究,纳入5个ICU的76例接受ECMO的COVID-19重症ARDS成人患者;ECMO启动前机械通气中位时间6天(IQR 3-10)。
  • ECMO启动时中位PaO2:FiO2为71 mmHg(IQR 62-81),中位PaCO2为58 mmHg(IQR 51-66),中位动脉pH为7.33(IQR 7.25-7.38)。
  • 45例(59%)脱离ECMO;28天、60天、90天生存率分别为92%、62%、51%。
  • 含RESP评分的多因素logistic回归:较高BMI与较高90天生存相关,OR 0.775(95%CI 0.644-0.934),p=0.007;年轻年龄与90天生存相关,OR 1.1354(95%CI 1.004-1.285),p=0.044。
  • 含PRESERVE评分的多因素logistic回归:较高BMI与较高90天生存相关,OR 0.631(95%CI 0.462-0.862);年轻年龄与90天生存相关,OR 1.187(95%CI 1.035-1.362),p=0.014。
  • 肥胖患者较非肥胖患者通气时使用更高PEEP,呼吸系统顺应性略高。

证据类型、等级与局限

  • 证据类型:双向观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在接受ECMO的COVID-19重症ARDS患者中,肥胖是与90天生存改善相关的独立因素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Since March 2020, health care systems were importantly affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, with some patients presenting severe acute respiratory distress syndrome (ARDS), requiring extra-corporeal membrane oxygenation (ECMO). We designed an ambispective observational cohort study including all consecutive adult patients admitted to 5 different ICUs from a university hospital. The main objective was to identify the risk factors of severe COVID-19 ARDS patients supported by ECMO associated with 90-day survival.

RESULTS: Between March 1st and November 30th 2020, 76 patients with severe COVID-19 ARDS were supported by ECMO. Median (interquartile range IQR) duration of mechanical ventilation (MV) prior to ECMO was of 6 (3-10) days. At ECMO initiation, patients had a median PaO2:FiO2 of 71 mmHg (IQR 62-81), median PaCO2 of 58 mmHg (IQR 51-66) and a median arterial pH of 7.33 (IQR 7.25-7.38). Forty-five patients (59%) were weaned from ECMO. Twenty-eight day, 60-day and 90-day survival rates were, respectively, 92, 62 and 51%. In multivariate logistic regression analysis, with 2 models, one with the RESP score and one with the PRESERVE score, we found that higher BMI was associated with higher 90-day survival [odds ratio (OR): 0.775 (0.644-0.934), p = 0.007) and 0.631 (0.462-0.862), respectively]. Younger age was also associated with 90-day survival in both models [OR: 1.1354 (1.004-1.285), p = 0.044 and 1.187 (1.035-1.362), p = 0.014 respectively]. Obese patients were ventilated with higher PEEP than non-obese patients and presented slightly higher respiratory system compliance.

CONCLUSION: In this ambispective observational cohort of COVID-19 severe ARDS supported by ECMO, obesity was an independent factor associated with improved survival at 90-day.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Daviet F, Guilloux P, Hraiech S, et al. Impact of obesity on survival in COVID-19 ARDS patients receiving ECMO: results from an ambispective observational cohort. Ann Intensive Care. 2021. PMID: 34779944. doi:10.1186/s13613-021-00943-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。